Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EXEL 
Exelixis Inc (EXEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: EXEL (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $44.42
1 Year Target Price $44.42
| 7 | Strong Buy |
| 4 | Buy |
| 9 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 38.68% | Avg. Invested days 49 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.89B USD | Price to earnings Ratio 19.44 | 1Y Target Price 44.42 |
Price to earnings Ratio 19.44 | 1Y Target Price 44.42 | ||
Volume (30-day avg) 20 | Beta 0.32 | 52 Weeks Range 25.17 - 49.62 | Updated Date 09/17/2025 |
52 Weeks Range 25.17 - 49.62 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 27.01% | Operating Margin (TTM) 37.58% |
Management Effectiveness
Return on Assets (TTM) 17.24% | Return on Equity (TTM) 29% |
Valuation
Trailing PE 19.44 | Forward PE 14.18 | Enterprise Value 9925330671 | Price to Sales(TTM) 4.88 |
Enterprise Value 9925330671 | Price to Sales(TTM) 4.88 | ||
Enterprise Value to Revenue 4.45 | Enterprise Value to EBITDA 12.7 | Shares Outstanding 269202521 | Shares Floating 231837211 |
Shares Outstanding 269202521 | Shares Floating 231837211 | ||
Percent Insiders 2.23 | Percent Institutions 96.95 |
Upturn AI SWOT
Exelixis Inc
Company Overview
History and Background
Exelixis, Inc. was founded in 1994 and is a biotechnology company focused on discovering, developing, and commercializing new medicines to treat cancer. Initially, the company focused on genomics-based drug discovery. Over time, it shifted its focus to small molecule therapeutics, particularly kinase inhibitors. Key milestones include the FDA approval of Cabometyx (cabozantinib) and Cometriq (cabozantinib).
Core Business Areas
- Oncology Therapeutics: Exelixis's primary business is the development and commercialization of oncology therapies, primarily kinase inhibitors for treating various cancers, including renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer.
Leadership and Structure
Exelixis is led by Vicki Goodman (acting CEO). The company operates with a functional organizational structure, encompassing research, development, commercial, and administrative functions. It has a board of directors responsible for oversight.
Top Products and Market Share
Key Offerings
- Cabometyx (cabozantinib): Cabometyx is a tyrosine kinase inhibitor approved for advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid cancer (DTC). Cabometyx faces competition from other tyrosine kinase inhibitors, such as sunitinib (Pfizer's Sutent) and nivolumab (Bristol-Myers Squibb's Opdivo). Exelixis reported 2023 revenue of approximately $1.6 Billion for Cabometyx. Market share within RCC, HCC, and DTC varies but is significant.
Market Dynamics
Industry Overview
The oncology therapeutics market is characterized by high growth, driven by an aging population, increased cancer incidence, and advancements in drug development. It is competitive with many large pharmaceutical companies.
Positioning
Exelixis positions itself as a specialized oncology company focused on developing and commercializing innovative kinase inhibitors. Its competitive advantage lies in its expertise in kinase biology and successful development of Cabometyx.
Total Addressable Market (TAM)
The global oncology therapeutics market is estimated to be hundreds of billions of dollars. Exelixis' positioning with Cabometyx allows it to capture a significant portion of the RCC, HCC, and DTC market segments. The Cabometyx market is valued at $1.6 Billion, but the overall oncology therapeutics market is several times larger.
Upturn SWOT Analysis
Strengths
- Successful development and commercialization of Cabometyx
- Strong expertise in kinase inhibitor development
- Experienced management team focused on oncology
- Solid financial position with growing revenue stream
Weaknesses
- Reliance on a limited number of products
- High dependence on Cabometyx for revenue
- Exposure to generic competition upon patent expiration
- Potential for clinical trial failures
Opportunities
- Expanding Cabometyx indications to other cancer types
- Developing new kinase inhibitors or other oncology therapies
- Partnering with other companies for drug development
- Acquiring complementary oncology assets
Threats
- Competition from other oncology therapies
- Regulatory hurdles and delays in drug approval
- Pricing pressures from payers
- Patent challenges and generic competition
Competitors and Market Share
Key Competitors
- PFE
- BMY
- MRK
Competitive Landscape
Exelixis competes with large pharmaceutical companies in the oncology market. Its competitive advantage lies in its specialization and expertise in kinase inhibitor development, but it faces challenges related to scale and resources compared to larger players.
Growth Trajectory and Initiatives
Historical Growth: Exelixis has experienced substantial growth in recent years, driven by the increasing adoption of Cabometyx.
Future Projections: Analysts project continued revenue growth for Exelixis, driven by further Cabometyx market penetration and potential new indications. Estimates varies from 5-10% per year.
Recent Initiatives: Exelixis is actively pursuing new drug development programs and exploring potential acquisitions or partnerships to expand its product pipeline.
Summary
Exelixis is a solid biotechnology company specializing in oncology with a strong revenue stream from Cabometyx. While heavily reliant on one product, it has demonstrated consistent growth and profitability. The company should focus on expanding its product pipeline and mitigating the risks associated with patent expirations, as well as the dependence on one major drug, Cabometyx. Its prospects looks bright overall.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Exelixis Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports (e.g., from major investment banks)
- Company press releases
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Exelixis Inc
Exchange NASDAQ | Headquaters Alameda, CA, United States | ||
IPO Launch date 2000-04-07 | CEO, President & Director Dr. Michael M. Morrissey Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1147 | Website https://www.exelixis.com |
Full time employees 1147 | Website https://www.exelixis.com | ||
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.